- Raw materials
- Antibacterials
- Echinomycin
Echinomycin API Manufacturers & Suppliers
0 verified results
All Echinomycin data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Echinomycin | CAS No: 512-64-1 | GMP-certified suppliers
A medication that exhibits antibacterial and antineoplastic activities by inhibiting nucleic acid synthesis, primarily used in experimental research for anti-infective and anticancer applications.
Therapeutic categories
Product Snapshot
- Echinomycin is categorized as a peptide antibiotic with an injectable formulation
- It is primarily utilized in oncology research for its antitumor properties
- The compound is currently designated as experimental and lacks approval from major regulatory agencies such as the FDA and EMA
Clinical Overview
Although echinomycin has demonstrated potent biological activity in preclinical studies, it remains experimental and is not currently approved for clinical use. Its pharmacodynamic profile is characterized by interference with nucleic acid synthesis, placing it within the class of nucleic acid synthesis inhibitors. The drug exhibits both antibacterial and antineoplastic properties, reflecting its broad potential utility in anti-infective and anticancer research contexts.
Pharmacokinetic data, including absorption, distribution, metabolism, and excretion (ADME) parameters of echinomycin, are limited in the public domain, consistent with its experimental status. Its cytotoxic profile necessitates careful evaluation as toxicological data indicate significant cellular toxicity, attributable to its mechanism of DNA intercalation and transcription inhibition.
Safety considerations for echinomycin must address its pronounced cytotoxicity, potential off-target effects, and lack of established therapeutic dosing regimens. Ongoing research is focused on optimizing its therapeutic index and elucidating detailed pharmacological properties.
From an API procurement perspective, sourcing echinomycin requires stringent quality control to ensure purity and consistency due to its complex peptide structure and sensitivity to degradation. Suppliers must adhere to good manufacturing practices (GMP) and provide thorough analytical characterization, including identity, potency, and impurity profiling, to meet regulatory and research standards.
Identification & chemistry
| Generic name | Echinomycin |
|---|---|
| Molecule type | Small molecule |
| CAS | 512-64-1 |
| UNII | TG824J6RQT |
| DrugBank ID | DB15582 |
Formulation & handling
- Echinomycin is a small molecule with low water solubility, requiring formulation strategies to enhance bioavailability for oral or injectable routes. Stability considerations should address its limited aqueous solubility to prevent precipitation during processing and storage. The compound's moderate LogP suggests balanced hydrophilic and lipophilic properties, influencing excipient selection and absorption profiles.
Regulatory status
Echinomycin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
